CLAIMS

1. An immediate release pharmaceutical formulation comprising, as active ingredient, a compound of formula (I):



(I)

wherein

$R^1$ represents $C_{1-2}$ alkyl substituted by one or more fluoro substituents;

$R^2$ represents hydrogen, hydroxy, methoxy or ethoxy; and

n represents 0, 1 or 2;

or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier; provided that when the active ingredient is other than in the form of a salt the formulation does not solely contain:

- a solution of one active ingredient and water;
- a solution of one active ingredient and dimethylsulphoxide; or
- a solution of one active ingredient in a mixture of ethanol : PEG 660 12-hydroxy stearate : water 5:5:90.

2. An immediate release pharmaceutical formulation as claimed in claim 1 comprising an acid addition salt of a compound of formula (I) and a pharmaceutically acceptable diluent or carrier.

3. An immediate release pharmaceutical formulation as claimed in claim 1 or 2 wherein the active ingredient is:

Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe);

Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe);

Ph(3-Cl)(5-$OCH_2CH_2F$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe);
Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab;
Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OH);
Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF);
Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OH);
Ph(3-Cl)(5-$OCH_2CH_2F$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab; or
Ph(3-Cl)(5-$OCH_2CH_2F$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OH).

4. A formulation as claimed in claim 1, 2 or 3 wherein the active ingredient is a crystalline salt of:
Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe);
Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe); or
Ph(3-Cl)(5-$OCH_2CH_2F$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe).

5. A formulation as claimed in any one of claims 1 to 4 wherein the active ingredient is an ethanesulfonic acid, *n*-propanesulfonic acid, benzenesulfonic acid, 1,5-naphthalenedisulfonic acid, or n-butanesulfonic acid addition salt of Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe) or Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe).

6. A formulation as claimed in any one of claims 1 to 5 wherein the active ingredient is Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe), benzene-sulfonic acid salt, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 5.9, 4.73, 4.09 and 4.08Å.

7. A formulation as claimed in any one of claims 1 to 5 wherein the active ingredient is Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe), hemi-1,5-naphthalenedisulfonic acid salt, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 18.3, 9.1, 5.6, 5.5, 4.13, 4.02, 3.86, 3.69 and 3.63Å.

8. A formulation as claimed in any one of claims 1 to 7 wherein the composition is a solid immediate release pharmaceutical formulation, an injectable immediate release pharmaceutical formulation or a liquid immediate release oral pharmaceutical formulation.

9. The use of a formulation as claimed in any one of claims 1 to 8 as a medicament.

10. The use of a formulation as claimed in any one of claims 1 to 8 in the manufacture of a medicament for the treatment of a cardiovascular disorder.

11. A method of treating a cardiovascular disorder in a patient suffering from, or at risk of, said disorder, which comprises administering to the patient a therapeutically effective amount of a pharmaceutical formulation as claimed in any one of claims 1 to 8.